Protein protects lung cancer cells from efforts to fix or kill them

February 28, 2008

A protein that helps lung cancer cells thrive appears to do so by blocking healthy cells’ ability to fix themselves when radiation or chemicals such as nicotine damage their DNA, according to a University of Florida study to be published Friday (Feb. 29) in the journal Molecular Cell.

High levels of the protein, known as Bc12, are found in the cells of lung cancer patients who smoke.

Previous UF research has shown that nicotine activates the protein, which helps tumor cells live long past their natural lifespan and resist chemotherapy. The new findings explain how the protein enables cancer cells to circumvent the body’s own efforts to change them back into healthy cells -- or evade treatments designed to kill them.

Cancer is frequently associated with the accumulation of genetic aberrations in cells’ chromosomes. If these damaged cells can’t access their built-in repair system and subsequently survive long enough to divide and multiply, they pass along their mutations.

“If a cell experiences DNA damage, often that DNA can be repaired. But we found that Bc12 can block the DNA repair mechanism, which promotes tumor formation and genetic instability,” said Dr. Xingming Deng, an assistant professor in UF’s College of Medicine who is affiliated with the UF Shands Cancer Center. “This is a very important fundamental mechanism that explains why this protein has (a cancer-forming) function.”

Researchers say just one cell that develops a genetic mutation and is unable to repair itself could be enough for a full-blown tumor to develop.

“Lung cancer is the No. 1 killer of all cancer types; it is the most dangerous,” Deng said. “We wanted to find a way to treat lung cancer, how to prevent lung cancer, because lung cancer prognosis is very poor.”

Nearly 162,000 people will die from lung cancer in 2008, accounting for about 29 percent of all cancer deaths, according to the American Cancer Society. More people die of lung cancer than of colon, breast and prostate cancers combined.

In the study, UF scientists performed a series of laboratory experiments on lung cancer cells in culture that illuminated the molecular chain of events that allows Bc12 to disrupt DNA repair.

Deng also plans to explore the possibility that nicotine-induced activation of Bc12 can be blocked to increase chemotherapy’s effectiveness.

“This will probably help us in the future find ways to prevent tumors,” said Deng, adding that the protein could be a target for drug development. “We can target this mechanism and somehow find a way to prevent tumor formation.”

Source: University of Florida

Explore further: The immune cells that help tumors instead of destroying them

Related Stories

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer-causing mutation suppresses immune system around tumours

December 12, 2017
Mutations in 'Ras' genes, which drive 25% of human cancers by causing tumour cells to grow, multiply and spread, can also protect cancer cells from the immune system, finds a new study from the Francis Crick Institute and ...

A cough that won't quit—is it lung cancer?

December 15, 2017
Coughing removes particles, mucus, irritants or fluids from the lungs. It may be caused by something in the air, such as cooking fumes, perfume or spices, or it may be related to congestion caused by a cold, allergies or ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

Scientists discover possible master switch for programming cancer immunotherapy

December 11, 2017
During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells ...

How defeating THOR could bring a hammer down on cancer

December 14, 2017
It turns out Thor, the Norse god of thunder and the Marvel superhero, has special powers when it comes to cancer too.

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.